Matthew R. Weir

1982–2025 年に発表

別表記
Matthew R Weir
168
論文数
25,880
被引用数
95
h 指数
166
i10 指数

被引用数

Matthew R. Weir の年別被引用数1983 年: 被引用 6 件1984 年: 被引用 1 件1985 年: 被引用 2 件1987 年: 被引用 1 件1988 年: 被引用 2 件1989 年: 被引用 1 件1990 年: 被引用 5 件1991 年: 被引用 5 件1992 年: 被引用 4 件1993 年: 被引用 6 件1994 年: 被引用 4 件1995 年: 被引用 5 件1996 年: 被引用 6 件1997 年: 被引用 16 件1998 年: 被引用 3 件1999 年: 被引用 18 件2000 年: 被引用 50 件2001 年: 被引用 57 件2002 年: 被引用 72 件2003 年: 被引用 100 件2004 年: 被引用 100 件2005 年: 被引用 111 件2006 年: 被引用 104 件2007 年: 被引用 117 件2008 年: 被引用 91 件2009 年: 被引用 90 件2010 年: 被引用 116 件2011 年: 被引用 134 件2012 年: 被引用 101 件2013 年: 被引用 116 件2014 年: 被引用 115 件2015 年: 被引用 141 件2016 年: 被引用 151 件2017 年: 被引用 164 件2018 年: 被引用 137 件2019 年: 被引用 578 件2020 年: 被引用 653 件2021 年: 被引用 686 件2022 年: 被引用 619 件2023 年: 被引用 491 件2024 年: 被引用 980 件2025 年: 被引用 445 件2026 年: 被引用 20 件1986 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,693 件、この内訳の 26.1%イギリス: 引用元論文 697 件、この内訳の 6.8%中国: 引用元論文 559 件、この内訳の 5.4%カナダ: 引用元論文 501 件、この内訳の 4.9%イタリア: 引用元論文 498 件、この内訳の 4.8%ドイツ: 引用元論文 480 件、この内訳の 4.6%オーストラリア: 引用元論文 373 件、この内訳の 3.6%フランス: 引用元論文 351 件、この内訳の 3.4%オランダ: 引用元論文 348 件、この内訳の 3.4%スペイン: 引用元論文 341 件、この内訳の 3.3%スイス: 引用元論文 245 件、この内訳の 2.4%日本: 引用元論文 240 件、この内訳の 2.3%
0%26.1%その他 29%

分野

  • Medicine86%
  • Biochemistry, Genetics and Molecular Biology6.8%
  • Nursing2.5%
  • Immunology and Microbiology0.7%
  • Neuroscience0.6%
  • Health Professions0.6%
  • その他2.8%

トピック

  • Chronic Kidney Disease and Diabetes6.5%
  • Dialysis and Renal Disease Management4.9%
  • Renal Transplantation Outcomes and Treatments4.9%
  • Blood Pressure and Hypertension Studies4.6%
  • Diabetes Treatment and Management4%
  • Potassium and Related Disorders3.3%
  • その他71.8%

共著者

全論文

検索で開く
  1. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Leah Karliner, Andrew S. Levey, Adrian Liew, Peter Lin, Andrea O. Y. Luk, V. Rodríguez Martínez, Andrew E. Moran, Mai Ánh Nguyễn, Gregorio T. Obrador, Dónal O’Donoghue, Meda E. Pavkov, Jessie Pavlinac, Neil R. Powe, Jesse C. Seegmiller, Jenny I. Shen, Rukshana Shroff, Laura Solá, Maarten W. Taal, James Tattersall, Joseph A. Vassalotti, Matthew R. Weir, Ella Zomer - Kidney International 2020 被引用: 573

  2. Hypertension in CKD: Core Curriculum 2019

    著者: , , , - American Journal of Kidney Diseases 2019 被引用: 572

  3. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gilbert Ledesma, Keung Lee, John Lentz, Steven Lupovitch, James M. Luther, Lon Lynn, Obadias Marquez, Mobeen Mazhar, David P. Morin, Joel Neutel, Yaa Oppong, M Pan Alvarez Osorio, Andres Patron, Walter Pharr, Mercedes Ponce de Leon, Lilia Rodriguez-Ables, Jeffrey B. Rosen, Issac Sachmechi, Ronald Surowitz, Larkin T. Wadsworth, Jeffrey D. Wayne, Zahid N. Zafar - JAMA 2023 被引用: 190

  4. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jens Leipziger, Amanda K. Leonberg‐Yoo, Edgar V. Lerma, Jose Ernesto Lopez-Almaraz, Jolanta Małyszko, Johannes F.E. Mann, Matti Marklund, Alicia A. McDonough, Masahiko Nagahama, Sankar D. Navaneethan, Bertram Pitt, Oleh Pochynyuk, Thyago Proença de Moraes, Zubaid Rafique, Bruce Robinson, Simon D. Roger, Patrick Rossignol, Adam J. Singer, Andrew Smyth, Manish M. Sood, Michael Walsh, Matthew R. Weir, Charles S. Wingo - Kidney International 2019 被引用: 477

  5. Cell-Free DNA and Active Rejection in Kidney Allografts

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2017 被引用: 566

  6. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Betty Muthoni Gikonyo, Dan Gikonyo, Roger J. Hajjar, Kunitoshi Iseki, Hideki Ishii, Greg Knoll, Colin R. Lenihan, Krista L. Lentine, Edgar V. Lerma, Etienne Macedo, Patrick B. Mark, Eisei Noiri, Alberto Palazzuoli, Roberto Pecoits‐Filho, Bertram Pitt, Claudio Rigatto, Patrick Rossignol, Soko Setoguchi, Manish M. Sood, Stefan Störk, Rita S. Suri, Karolina Szummer, Sydney Tang, Navdeep Tangri, Aliza Thompson, Krishnaswami Vijayaraghavan, Michael D. Walsh, Angela Yee‐Moon Wang, Matthew R. Weir - Kidney International 2019 被引用: 435

  7. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aleksandr Parkhomenko, Piotr Ponikowski, Petar Seferović, Michele Senni, Е. V. Shlyakhto, Alain Cohen‐Solal, Peter Szecsödy, Klaus Jensen, Fabio Dorigotti, Matthew R. Weir, Bertram Pitt - European Heart Journal 2022 被引用: 222

  8. Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

    著者: , , , , , , , , , , , , - Kidney International 2020 被引用: 212

  9. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takayuki Hamano, Chuan‐Ming Hao, Raymond K. Hsu, Kunitoshi Iseki, Isabelle Jordans, Edgar V. Lerma, Francesco Locatelli, Iain C. Macdougall, Jolanta Małyszko, Patrick H. Maxwell, Lawrence P. McMahon, Gregorio T. Obrador, Marlies Ostermann, Roberto Pecoits‐Filho, Farzana Perwad, Simon D. Roger, Ajay Singh, Laura Solá, Bruce Spinowitz, Mai Sugahara, Toshiyuki Takahashi, Mototsugu TANAKA, Tetsuhiro Tanaka, Der‐Cherng Tarng, Marcello Tonelli, Yusuke Tsukamoto, Carl P. Walther, Angela Yee‐Moon Wang, Hong Kong, Bradley A. Warady, Angela C Webster, Matthew R. Weir, Jay B. Wish, Muh Geot Wong - Kidney International 2023 被引用: 136

  10. Risk Factors for CKD Progression

    著者: , , , , , , , , , , , , , , , - Clinical Journal of the American Society of Nephrology 2020 被引用: 158

  11. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study

    著者: , , , , , , , , , , , , , , , , , , , - Kidney International 2021 被引用: 179

  12. Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study

    著者: , , , , , , , , , , , , , , , , , , , - American Journal of Kidney Diseases 2020 被引用: 179

  13. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan G. Jardine, David W. Johnson, Min Jun, Laura Labriola, Patrick B. Mark, Peter A. McCullough, Thomas D. Nolin, Tatjana Potpara, Patrick H. Pun, Antônio Luiz Pinho Ribeiro, Patrick Rossignol, Jenny I. Shen, Manish M. Sood, Yusuke Tsukamoto, Angela Yee‐Moon Wang, Matthew R Weir, James B. Wetmore, Jerzy Krzysztof Wranicz, Hiro Yamasaki - European Heart Journal 2018 被引用: 286

  14. Albuminuria and Heart Failure

    著者: , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 被引用: 110

  15. Abnormalities of Potassium in Heart Failure

    著者: , , , , , , , , , - Journal of the American College of Cardiology 2020 被引用: 178

  16. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

    著者: , , , , , , , , , , , , - Endocrine Practice 2016 被引用: 357

  17. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

    著者: , , , , , , , , , - New England Journal of Medicine 2014 被引用: 658

  18. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases

    著者: , , , , , , , , , , , , , , , , - Journal of Diabetes and its Complications 2023 被引用: 97

  19. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Norman E. Lepor, Christos S. Mantzoros, Chantal Mathieu, Christian W. Mende, Erin D. Michos, Javier Morales, Jorge Plutzky, Richard E. Pratley, Kausik K Ray, Peter Rossing, Naveed Sattar, Peter E.H. Schwarz, Eberhard Standl, Philippe Gabríel Steg, Lâle Tokgözoğlu, Jaakko Tuomilehto, Guillermo E Umpierrez, Paul Valensi, Matthew R. Weir, John Wilding, Eugene E. Wright - Metabolism 2024 被引用: 76

  20. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease

    著者: , , , , , , , , , - JAMA 2015 被引用: 437

  21. Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease

    著者: , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 被引用: 109

  22. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew R. Weir - Journal of Diabetes and its Complications 2021 被引用: 62

  23. Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine

    著者: , - Archives of Internal Medicine 2000 被引用: 818

  24. The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease

    著者: , , , , , , , - Archives of Internal Medicine 2009 被引用: 643